Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition

Group 1 - Novartis AG plans to acquire Tourmaline Bio for $1.4 billion, enhancing its defensive stock profile [1][2] - The acquisition will provide access to pacibekitug, a drug in Phase III trials aimed at treating systemic inflammation and atherosclerotic cardiovascular disease [2][3] - The deal is expected to close in the fourth quarter, with Tourmaline becoming a wholly-owned subsidiary of Novartis [3] Group 2 - Novartis focuses on innovative medicines across various therapeutic areas, including cardiovascular, renal, metabolic diseases, oncology, immunology, and neurology [4]